http://www.sciencedaily.com/news/health_medicine/men's_health/ Men's health and fitness. Learn about prostate cancer, erectile dysfunction, and other conditions affecting men. Browse medical research on early detection, symptoms and new treatments. en-us Sat, 18 May 2013 21:03:56 EDT Sat, 18 May 2013 21:03:56 EDT 60 http://www.sciencedaily.com/images/logosmall.gif http://www.sciencedaily.com/news/health_medicine/men's_health/ For more science articles, visit ScienceDaily. http://www.sciencedaily.com/releases/2013/05/130513083044.htm A new analysis has found a link between exposure to Agent Orange and lethal forms of prostate cancer among US Veterans. The findings suggest that Agent Orange exposure history should be incorporated into prostate screening decisions for Veterans. Mon, 13 May 2013 08:30:30 EDT http://www.sciencedaily.com/releases/2013/05/130513083044.htm http://www.sciencedaily.com/releases/2013/05/130508114307.htm Tomatoes and soy foods may be more effective in preventing prostate cancer when they are eaten together than when either is eaten alone, said a new study. Wed, 08 May 2013 11:43:43 EDT http://www.sciencedaily.com/releases/2013/05/130508114307.htm http://www.sciencedaily.com/releases/2013/05/130507154934.htm Scientists have solved the mystery of why a substantial percentage of castrate-resistant metastatic prostate cancer cells contain abnormally high levels of the pro-growth protein Stat5. Tue, 07 May 2013 15:49:49 EDT http://www.sciencedaily.com/releases/2013/05/130507154934.htm http://www.sciencedaily.com/releases/2013/05/130507061137.htm Problems falling asleep and staying asleep increased the risk for prostate cancer. The association was stronger for advanced disease. Larger studies with longer follow-up are necessary for confirmation. Tue, 07 May 2013 06:11:11 EDT http://www.sciencedaily.com/releases/2013/05/130507061137.htm http://www.sciencedaily.com/releases/2013/05/130506094912.htm Patients with prostate cancer that has metastasized, or spread, to other parts of the body face a significantly higher risk of dying when visiting a hospital emergency department on the weekend instead of on a weekday, according to researchers. Mon, 06 May 2013 09:49:49 EDT http://www.sciencedaily.com/releases/2013/05/130506094912.htm http://www.sciencedaily.com/releases/2013/05/130502093510.htm Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don’t take such medication, according to new study. Thu, 02 May 2013 09:35:35 EDT http://www.sciencedaily.com/releases/2013/05/130502093510.htm http://www.sciencedaily.com/releases/2013/04/130429133542.htm The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers found. Mon, 29 Apr 2013 13:35:35 EDT http://www.sciencedaily.com/releases/2013/04/130429133542.htm http://www.sciencedaily.com/releases/2013/04/130423134019.htm Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to new data. Tue, 23 Apr 2013 13:40:40 EDT http://www.sciencedaily.com/releases/2013/04/130423134019.htm http://www.sciencedaily.com/releases/2013/04/130422101139.htm A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease. The study provides valuable information on the genetics of prostate cancer and offers insights into which patients should be treated aggressively. Mon, 22 Apr 2013 10:11:11 EDT http://www.sciencedaily.com/releases/2013/04/130422101139.htm http://www.sciencedaily.com/releases/2013/04/130416214736.htm Focusing prostate cancer testing on men at highest risk of developing the disease is likely to improve the ratio between benefits and the harms of screening, a new paper suggests. Tue, 16 Apr 2013 21:47:47 EDT http://www.sciencedaily.com/releases/2013/04/130416214736.htm http://www.sciencedaily.com/releases/2013/04/130415151442.htm Scientists have identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the finding not only may help determine which patients require additional treatment after surgery, it also may help address the most challenging problem in prostate cancer treatment -- distinguishing tumors that require aggressive treatment from those that can safely be monitored. Mon, 15 Apr 2013 15:14:14 EDT http://www.sciencedaily.com/releases/2013/04/130415151442.htm http://www.sciencedaily.com/releases/2013/04/130415124817.htm Men with a common condition that causes frequent nighttime trips to the bathroom can get relief with a minimally invasive treatment that shrinks the prostate, suggests a new study. The early findings hail from the first prospective US trial of prostatic artery embolization, which reduces blood flow to the prostate, thus shrinking it. Mon, 15 Apr 2013 12:48:48 EDT http://www.sciencedaily.com/releases/2013/04/130415124817.htm http://www.sciencedaily.com/releases/2013/04/130415094830.htm Genetic variants have been identified which can increase serum prostate specific antigen (PSA) concentrations and prostate cancer risk. A new study reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others. Mon, 15 Apr 2013 09:48:48 EDT http://www.sciencedaily.com/releases/2013/04/130415094830.htm http://www.sciencedaily.com/releases/2013/04/130409173238.htm The most recent in a series of studies has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells. Tue, 09 Apr 2013 17:32:32 EDT http://www.sciencedaily.com/releases/2013/04/130409173238.htm http://www.sciencedaily.com/releases/2013/04/130409111559.htm Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease. Tue, 09 Apr 2013 11:15:15 EDT http://www.sciencedaily.com/releases/2013/04/130409111559.htm http://www.sciencedaily.com/releases/2013/04/130408184457.htm Men between the ages of 50 and 69 should discuss the limited benefits and substantial harms of the prostate-specific antigen test with their doctor before undergoing screening for prostate cancer, according to new recommendations issued today by the American College of Physicians. Mon, 08 Apr 2013 18:44:44 EDT http://www.sciencedaily.com/releases/2013/04/130408184457.htm http://www.sciencedaily.com/releases/2013/04/130408142644.htm Researchers have discovered that a genetically engineered Newcastle disease virus, which harms chickens but not humans, kills prostate cancer cells of all kinds, including hormone-resistant cancer cells. Mon, 08 Apr 2013 14:26:26 EDT http://www.sciencedaily.com/releases/2013/04/130408142644.htm http://www.sciencedaily.com/releases/2013/04/130405064405.htm Non-invasive ‘liquid biopsies’ can find metastatic or recurrent prostate cancer, in a low cost assay suitable for most healthcare systems, finds new research. Genomic signatures of prostate cancer, isolated from plasma DNA, display abnormal copy numbers of specific areas of chromosomes. It is even possible to separate out patients who develop resistance against hormone deprivation therapy, which is the most common form of treatment in men with metastatic prostate cancer. Fri, 05 Apr 2013 06:44:44 EDT http://www.sciencedaily.com/releases/2013/04/130405064405.htm http://www.sciencedaily.com/releases/2013/04/130404092833.htm A new article recommends a dramatic shift in treating metastatic prostate cancer. Hormone therapy has been shown to extend the lives of patients, but it causes unpleasant side effects in men like moodiness, hot flashes, bone loss and sexual dysfunction. To relieve patients, doctors "pulsed" the therapy -- giving it for a time and then stopping until signs of prostate cancer activity reappear. The study shows that continuous therapy helps more. Thu, 04 Apr 2013 09:28:28 EDT http://www.sciencedaily.com/releases/2013/04/130404092833.htm http://www.sciencedaily.com/releases/2013/04/130403200011.htm Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds. Wed, 03 Apr 2013 20:00:00 EDT http://www.sciencedaily.com/releases/2013/04/130403200011.htm http://www.sciencedaily.com/releases/2013/04/130402150147.htm SPDEF acts as a switch, regulating production of E-Cadherin, the loss of which is a prerequisite of metastasis in many cancers. Tue, 02 Apr 2013 15:01:01 EDT http://www.sciencedaily.com/releases/2013/04/130402150147.htm http://www.sciencedaily.com/releases/2013/04/130401181504.htm Researchers have found that the enzyme PKCzeta controls the activation of a pro-tumor gene called c-Myc. Normally, PKCzeta's alteration keeps c-Myc in check. But PKCzeta levels are low in prostate and other cancers, leaving c-Myc free to enhance cell growth and metastasis. Mon, 01 Apr 2013 18:15:15 EDT http://www.sciencedaily.com/releases/2013/04/130401181504.htm http://www.sciencedaily.com/releases/2013/04/130401120911.htm Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study. Mon, 01 Apr 2013 12:09:09 EDT http://www.sciencedaily.com/releases/2013/04/130401120911.htm http://www.sciencedaily.com/releases/2013/03/130327132441.htm Scientists have discovered the driving force behind the development of prostate cancer. Their research reveals the existence of a cancer inducing DNA re-alignment in stem cells taken from human prostate cancers. Wed, 27 Mar 2013 13:24:24 EDT http://www.sciencedaily.com/releases/2013/03/130327132441.htm http://www.sciencedaily.com/releases/2013/03/130326133208.htm Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, according to new research. Tue, 26 Mar 2013 13:32:32 EDT http://www.sciencedaily.com/releases/2013/03/130326133208.htm http://www.sciencedaily.com/releases/2013/03/130318132629.htm Researchers have discovered that the protein Siah2 keeps a portion of androgen receptors constantly active, allowing prostate cancer cells to resist treatment. Based on this new information, Siah2 could make a promising biomarker for tracking a prostate cancer patient's response to therapy. Inhibiting Siah2's interaction with the androgen receptor complex might also provide a new method for re-sensitizing castration-resistant prostate tumors to hormone therapy. Mon, 18 Mar 2013 13:26:26 EDT http://www.sciencedaily.com/releases/2013/03/130318132629.htm http://www.sciencedaily.com/releases/2013/03/130315202704.htm Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study. Fri, 15 Mar 2013 20:27:27 EDT http://www.sciencedaily.com/releases/2013/03/130315202704.htm http://www.sciencedaily.com/releases/2013/03/130315074701.htm Surgery offers better survival benefit for men with localized prostate cancer, according to a large observational study. Fri, 15 Mar 2013 07:47:47 EDT http://www.sciencedaily.com/releases/2013/03/130315074701.htm http://www.sciencedaily.com/releases/2013/03/130305174650.htm For men with low-risk prostate cancer, focal laser ablation treats just the diseased portion of the prostate rather than the entire gland. A phase 1 trial found it was safe. None of the nine men in the study had a significant side effect. Seven of the nine patients had no evidence of disease six months later. Tue, 05 Mar 2013 17:46:46 EST http://www.sciencedaily.com/releases/2013/03/130305174650.htm http://www.sciencedaily.com/releases/2013/03/130305131156.htm Two novel radiolabeled small molecules targeting prostate-specific membrane antigen have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to new research. The imaging agents -- 123I-MIP-1072 and 123I-MIP-1095 -- were shown to have a high sensitivity of lesion detection in bone, soft tissue and the prostate gland with minimal retention in non-target tissue. Tue, 05 Mar 2013 13:11:11 EST http://www.sciencedaily.com/releases/2013/03/130305131156.htm http://www.sciencedaily.com/releases/2013/03/130304123242.htm Scientists have developed a new paradigm to assess hereditary risk prediction in common diseases, such as prostate cancer. Mon, 04 Mar 2013 12:32:32 EST http://www.sciencedaily.com/releases/2013/03/130304123242.htm http://www.sciencedaily.com/releases/2013/02/130226101301.htm A new study has analyzed 25 years of follow-up data after radiation therapy treatment for prostate cancer patients. Tue, 26 Feb 2013 10:13:13 EST http://www.sciencedaily.com/releases/2013/02/130226101301.htm http://www.sciencedaily.com/releases/2013/02/130225153141.htm A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a new article. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally. Mon, 25 Feb 2013 15:31:31 EST http://www.sciencedaily.com/releases/2013/02/130225153141.htm http://www.sciencedaily.com/releases/2013/02/130220132005.htm A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, researchers have found. Wed, 20 Feb 2013 13:20:20 EST http://www.sciencedaily.com/releases/2013/02/130220132005.htm http://www.sciencedaily.com/releases/2013/02/130214194059.htm Even in the presence of screening, there is benefit to radical prostatectomy (RP) in prostate cancer patients, however, the benefit is limited to a subgroup of patients and can take years to become evident according to a study. Thu, 14 Feb 2013 19:40:40 EST http://www.sciencedaily.com/releases/2013/02/130214194059.htm http://www.sciencedaily.com/releases/2013/02/130211134804.htm While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which causes the disease at a later age. Their findings might have important consequences for the diagnosis and treatment of prostate cancer in younger patients. Mon, 11 Feb 2013 13:48:48 EST http://www.sciencedaily.com/releases/2013/02/130211134804.htm http://www.sciencedaily.com/releases/2013/02/130211091022.htm A new study suggests that exercise may reduce Caucasian men's risk of developing prostate cancer. And among Caucasian men who do have prostate cancer, exercise may reduce their risk of having more serious forms of the disease. Unfortunately, the benefits do not seem to apply to African-American men. Mon, 11 Feb 2013 09:10:10 EST http://www.sciencedaily.com/releases/2013/02/130211091022.htm http://www.sciencedaily.com/releases/2013/02/130201114402.htm The use of volume-modulated arc therapy to deliver intensity-modulated radiation therapy to prostate cancer patients results in an overall reduction in treatment time of approximately 14 percent, a new study suggests. Fri, 01 Feb 2013 11:44:44 EST http://www.sciencedaily.com/releases/2013/02/130201114402.htm http://www.sciencedaily.com/releases/2013/01/130130184322.htm A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. Wed, 30 Jan 2013 18:43:43 EST http://www.sciencedaily.com/releases/2013/01/130130184322.htm http://www.sciencedaily.com/releases/2013/01/130128142849.htm Regular consumption of deep-fried foods such as French fries, fried chicken and doughnuts is associated with an increased risk of prostate cancer, and the effect appears to be slightly stronger with regard to more aggressive forms of the disease, according to a new study. Mon, 28 Jan 2013 14:28:28 EST http://www.sciencedaily.com/releases/2013/01/130128142849.htm http://www.sciencedaily.com/releases/2013/01/130125142042.htm Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer. Fri, 25 Jan 2013 14:20:20 EST http://www.sciencedaily.com/releases/2013/01/130125142042.htm http://www.sciencedaily.com/releases/2013/01/130123115413.htm A new study reports that high blood calcium levels might predict of ovarian cancer, the most fatal of the gynecologic cancers. Wed, 23 Jan 2013 11:54:54 EST http://www.sciencedaily.com/releases/2013/01/130123115413.htm http://www.sciencedaily.com/releases/2013/01/130122101634.htm The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness. Tue, 22 Jan 2013 10:16:16 EST http://www.sciencedaily.com/releases/2013/01/130122101634.htm http://www.sciencedaily.com/releases/2013/01/130117183138.htm In what is believed to be the first study to describe the impact on men with a ‘high’ risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research shows this population to have a higher fracture incidence following treatment completion. Thu, 17 Jan 2013 18:31:31 EST http://www.sciencedaily.com/releases/2013/01/130117183138.htm http://www.sciencedaily.com/releases/2013/01/130117105831.htm An annual report from the American Cancer Society finds as of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately 1.2 million deaths from cancer, 152,900 of these in 2009 alone. Thu, 17 Jan 2013 10:58:58 EST http://www.sciencedaily.com/releases/2013/01/130117105831.htm http://www.sciencedaily.com/releases/2013/01/130115111543.htm Measurements taken over time of prostate specific antigen, the most commonly used screening test for prostate cancer in men, improve the accuracy of aggressive prostate cancer detection when compared to a single measurement of PSA, according to a new study. Tue, 15 Jan 2013 11:15:15 EST http://www.sciencedaily.com/releases/2013/01/130115111543.htm http://www.sciencedaily.com/releases/2013/01/130109162032.htm The rate of prostate cancer occurrence in Asian cultures is similar to the rate in Western cultures, but in the West, prostate cancer tends to progress, whereas in Asian cultures it does not. Why? A University of Colorado Cancer Center study published in the January 2013 issue of the journal Cancer Prevention Research shows that the answer may be a high-fiber diet. Wed, 09 Jan 2013 16:20:20 EST http://www.sciencedaily.com/releases/2013/01/130109162032.htm http://www.sciencedaily.com/releases/2013/01/130104143449.htm The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness have been reported. Fri, 04 Jan 2013 14:34:34 EST http://www.sciencedaily.com/releases/2013/01/130104143449.htm http://www.sciencedaily.com/releases/2013/01/130103073050.htm Prostate cancer experts have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. Thu, 03 Jan 2013 07:30:30 EST http://www.sciencedaily.com/releases/2013/01/130103073050.htm http://www.sciencedaily.com/releases/2013/01/130102140537.htm Researchers at Dana-Farber/Brigham and Women's Cancer Center report a small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, causing them to regret the type of treatment they chose. Wed, 02 Jan 2013 14:05:05 EST http://www.sciencedaily.com/releases/2013/01/130102140537.htm http://www.sciencedaily.com/releases/2012/12/121221123321.htm Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients. Fri, 21 Dec 2012 12:33:33 EST http://www.sciencedaily.com/releases/2012/12/121221123321.htm http://www.sciencedaily.com/releases/2012/12/121220143934.htm Researchers have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers. Thu, 20 Dec 2012 14:39:39 EST http://www.sciencedaily.com/releases/2012/12/121220143934.htm http://www.sciencedaily.com/releases/2012/12/121220101929.htm Mice deficient in PTEN in the prostate developed stable precancers. Androgen deprivation promoted progression to invasive prostate cancer. Patients with PTEN-deficient prostate precancers may not benefit from androgen deprivation chemoprevention therapy. Thu, 20 Dec 2012 10:19:19 EST http://www.sciencedaily.com/releases/2012/12/121220101929.htm http://www.sciencedaily.com/releases/2012/12/121218121558.htm A new Australian study shows that large regions of the genome -- amounting to roughly 2 percent -- are epigenetically activated in prostate cancer. Regions activated contain many prostate cancer-specific genes, including PSA (prostate specific antigen) and PCA3, the most common prostate cancer markers. Until now, these genes were not known to be regulated epigenetically. Tue, 18 Dec 2012 12:15:15 EST http://www.sciencedaily.com/releases/2012/12/121218121558.htm http://www.sciencedaily.com/releases/2012/12/121218081445.htm Researchers have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer. Tue, 18 Dec 2012 08:14:14 EST http://www.sciencedaily.com/releases/2012/12/121218081445.htm http://www.sciencedaily.com/releases/2012/12/121213172308.htm Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation treatment called intensity modulated radiotherapy, researchers report. Thu, 13 Dec 2012 17:23:23 EST http://www.sciencedaily.com/releases/2012/12/121213172308.htm http://www.sciencedaily.com/releases/2012/12/121213142313.htm Scientists have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say that identifying the previously unknown protein function could serve as a treatment target for prostate cancers that are no longer controlled by hormone-blocking drugs. Thu, 13 Dec 2012 14:23:23 EST http://www.sciencedaily.com/releases/2012/12/121213142313.htm http://www.sciencedaily.com/releases/2012/12/121210132754.htm Ground-breaking research by physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy. Mon, 10 Dec 2012 13:27:27 EST http://www.sciencedaily.com/releases/2012/12/121210132754.htm http://www.sciencedaily.com/releases/2012/12/121204145920.htm Medical researchers have described the modern state of prostate cancer care -- examining not only new drugs but entirely new classes of drugs that may be effective and well-tolerated in an aging population. Tue, 04 Dec 2012 14:59:59 EST http://www.sciencedaily.com/releases/2012/12/121204145920.htm http://www.sciencedaily.com/releases/2012/12/121204145657.htm A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a new study. Tue, 04 Dec 2012 14:56:56 EST http://www.sciencedaily.com/releases/2012/12/121204145657.htm